S. Nissen
Endocrinology, Diabetes and Metabolism · 2003–2021
A researcher in the Science corpus: 12 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.
Subfields
- Endocrinology, Diabetes and Metabolism — 46 citations into it
- Molecular Biology — 16 citations into it
Whom S. Nissen trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts S. Nissen overall
Papers from S. Nissen's perspective
Ordered by how strongly the researchers S. Nissen trusts endorse each paper. Same corpus, a different order for every researcher.
- Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. (Journal of the American Medical Association (JAMA))
- Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. (New England Journal of Medicine)
- Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. (The Lancet)
- Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. (New England Journal of Medicine)
- Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. (Journal of the American Medical Association (JAMA))
- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. (The Lancet)
- Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. (Journal of the American Medical Association (JAMA))
- [Bariatric surgery versus conventional medical therapy for type 2 diabetes]. (Revista clínica española (Ed. impresa))
- Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. (Journal of the American Medical Association (JAMA))
- Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 Years After Bariatric Surgery
Their papers
- Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. (2010) — 614 citations
- Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis (2021) — 619 citations
- Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes (2017) — 2,244 citations
- Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease (2017) — 692 citations
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated Patients: The GLAGOV Randomized Clinical Trial. (2016) — 1,077 citations
- 2014 ACC/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). (2015) — 669 citations
- Bariatric surgery versus intensive medical therapy for diabetes--3-year outcomes. (2014) — 1,647 citations
- Alogliptin after acute coronary syndrome in patients with type 2 diabetes. (2013) — 2,419 citations
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with Diabetes (2012) — 1,077 citations
- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. (2006) — 2,091 citations
- Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. (2005) — 705 citations
- Prognostic value of myeloperoxidase in patients with chest pain. (2003) — 1,125 citations